Silo Pharma, INC

Silo Pharma announced it has regained compliance with Nasdaq's minimum closing bid price requirement, a matter now considered closed by the exchange.

Silo Pharma, Inc. has filed a Certificate of Change to implement a 1-for-15 reverse stock split, effective June 2, 2026, adjusting its common stock structure and authorized shares.

Silo Pharma, Inc. will implement a 1-for-15 reverse stock split and reduce its authorized shares, effective June 2, 2026.

Silo Pharma's Board approved a $1 million share repurchase program and issued 848,320 common shares to an investor relations consultant as a $250,000 commitment fee.

Silo Pharma, Inc. has received an extension from Nasdaq until June 22, 2026, to regain compliance with the minimum $1.00 bid price requirement, avoiding immediate delisting.

Silo Pharma, Inc. shareholders approved an expanded equity incentive plan and granted the Board discretion to implement a reverse stock split at their annual meeting on October 24, 2025.

Silo Pharma reported an increased net loss in Q3 2025, driven by higher R&D expenses and accelerated license amortization, while launching a new cryptocurrency treasury strategy.

Silo Pharma, a biopharmaceutical company, reported a significantly wider net loss for the first half of 2025 while announcing a new cryptocurrency treasury strategy and facing a Nasdaq minimum bid price deficiency.

Silo Pharma reports a net loss for Q1 2025 while advancing its pipeline of novel therapeutics targeting PTSD, fibromyalgia, Alzheimer's, and multiple sclerosis.

Silo Pharma's Q3 2024 report reveals increased research and development expenses and recent capital raises, alongside a net loss of $2.66 million for the nine-month period.

Silo Pharma's second quarter 2024 results show a net loss, but the company is progressing with its drug development programs and has secured additional funding.

Silo Pharma reported a net loss of $801,667 for the first quarter of 2024, while advancing its pipeline of novel therapeutics.

Silo Pharma, a developmental-stage biopharmaceutical and cryptocurrency company, reported a net loss of $4.2 million for 2025 while advancing its drug pipeline and managing a volatile digital asset treasury.

Silo Pharma's 10-K filing highlights advancements in its drug development pipeline, including SPC-15 for PTSD and SPC-14 for Alzheimer's, while addressing financial and operational risks.

Silo Pharma's annual 10-K filing provides a comprehensive overview of its securities, financial condition, and ongoing research and development programs.

Silo Pharma's CEO and Director, Eric Weisblum, increased his direct beneficial ownership of common stock through open market purchases.

Silo Pharma CEO Eric Weisblum increased his direct ownership in the company by purchasing 2,000 shares of common stock over two days in November 2025.

Silo Pharma's CEO, Eric Weisblum, increased his direct ownership in the company by purchasing 12,000 shares of common stock over two days in November 2025.

Silo Pharma, Inc.'s Chief Executive Officer and Director, Eric Weisblum, acquired an additional 10,000 shares of common stock on May 27, 2025, increasing his direct beneficial ownership to 197,932 shares.

Silo Pharma, Inc. Director Wayne Linsley was granted 50,000 stock options with an exercise price of $0.429, vesting one year from the grant date, under the company's 2020 Omnibus Equity Incentive Plan.

Silo Pharma, Inc. Director Kevin Munoz was granted 50,000 stock options with an exercise price of $0.429, vesting in one year, as part of the company's 2020 Omnibus Equity Incentive Plan.

Silo Pharma, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for August 14, 2026, to elect directors, ratify auditors, and approve a significant increase in authorized common stock.

Silo Pharma, Inc. announced its 2025 Annual Meeting agenda, including director elections, auditor ratification, a proposed reverse stock split, and an equity incentive plan amendment.

Silo Pharma, Inc. announces its 2025 Annual Meeting of Shareholders to vote on director elections, auditor ratification, a reverse stock split, and an equity plan amendment.

Silo Pharma has announced its 2024 Annual Meeting of Stockholders to be held on December 20, 2024, where shareholders will vote on the election of directors, ratification of the accounting firm, executive compensation, and other key proposals.

Silo Pharma has rescheduled its 2024 annual meeting of stockholders from November 12, 2024, to December 20, 2024, and established a new record date.

Silo Pharma will hold its annual meeting of stockholders on November 12, 2024, to vote on director elections, auditor ratification, executive compensation, and other proposals.

Silo Pharma, a biopharmaceutical and cryptocurrency treasury company, filed an S-1 registration statement for the resale of up to 3,071,428 common shares underlying previously issued warrants.

Silo Pharma updates its registration statement for a proposed offering of common stock, warrants, and pre-funded warrants to fuel its biopharmaceutical development.

Silo Pharma enters into an agreement with H.C. Wainwright & Co. to serve as the exclusive underwriter, agent, or advisor for any securities offerings during the term of the agreement.

Silo Pharma launches a public offering of common stock and warrants, aiming to raise approximately $4.3 million for working capital to support its biopharmaceutical development programs.

Silo Pharma has filed a registration statement for the resale of up to 820,911 shares of its common stock upon the exercise of outstanding warrants.

Silo Pharma, Inc. has filed an amendment to its S-1 registration statement, aiming to register 1,043,739 shares of common stock for resale, primarily issuable upon the exercise of warrants, with potential proceeds directed towards product development and general corporate purposes.

AdvisorShares Trust has reported beneficial ownership of 75,582 shares, representing 6.69% of Silo Pharma, Inc.'s common stock, as of June 30, 2026.

Anson Funds Management LP and affiliated entities have disclosed a 4.9% beneficial ownership stake in Silo Pharma, Inc., primarily through common stock and exercisable warrants.

Intracoastal Capital LLC and its principals, Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Silo Pharma, Inc. as of December 31, 2025.

SEG Opportunity Fund, LLC has reported a 0.0% beneficial ownership in Silo Pharma, Inc., indicating a full divestment of its previously held stake.

Anson Funds Management LP and affiliated entities have reported a 7.2% beneficial ownership stake in Silo Pharma, Inc., totaling 952,381 shares of common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a continued beneficial ownership of 9.99% in Silo Pharma, Inc. common stock as of September 30, 2025.